Additive antinociceptive effect of the combination of diazoxide, an activator of ATP-sensitive K+ channels, and sodium nitroprusside and dibutyryl-cGMP

Eur J Pharmacol. 2004 Apr 5;489(1-2):59-65. doi: 10.1016/j.ejphar.2004.02.022.

Abstract

Using the rat paw pressure test, in which increased sensitivity is induced by intraplantar injection of prostaglandin E2, we assessed the antinociceptive effect of the ATP-sensitive K+ channel opener diazoxide and the large-conductance Ca(2+)-activated K+ channel opener NS-1619 (1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl) phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one) on the peripheral hyperalgesia induced by prostaglandin E2. Diazoxide, administered locally into the right hindpaw (20, 38, 75, 150, 300 and 600 microg), elicited a dose-dependent antinociceptive effect on prostaglandin E2-induced hyperalgesia (2 microg/paw). The effect of diazoxide at the dose of 300 microg/paw was shown to be local since it did not produce any effect when administered in the contralateral paw. The action of diazoxide (300 microg/paw) as an ATP-sensitive K+ channel opener seems to be specific, since its effect was antagonized in a dose-dependent manner by glibenclamide (40, 80 and 160 microg/paw), a specific blocker of these channels, while tetraethylammonium (7.5, 15 and 30 microg/paw), dequalinium (12.5, 25 and 50 microg/paw) or charybdotoxin (0.5, 1 and 2 microg/paw), blockers of voltage-dependent K+ channels and of small- and large-conductance Ca(2+)-activated K+ channels, respectively, were not able to abolish the antinociception induced by diazoxide. The peripheral antinociceptive effect of diazoxide was not prevented by prior administration of naloxone (12.5, 25 and 50 microg/paw), an opioid receptor antagonist, or methylene blue (75, 125 and 300 microg/paw), an agent that inhibits the activation of guanylate cyclase by nitric oxide. A low dose of diazoxide (20 microg/paw) administered together with a low dose of sodium nitroprusside (125 microg/paw) or dibutyryl cGMP (db-cGMP, 50 microg/paw) induced a marked antinociceptive effect similar to that observed when each drug was administered alone. NS1619 (75, 150 and 300 microg/paw), a specific opener of large-conductance Ca(2+)-activated K+ channels, had no antinociceptive action on prostaglandin E2-induced hyperalgesia. This series of experiments provides evidence for a peripheral antinociceptive action of diazoxide and supports the suggestion that the activation of ATP-sensitive K+ channels could be the mechanism by which sodium nitroprusside and db-cGMP induce peripheral antinociception, excluding the involvement of large-contuctance Ca(2+)-activated K+ channels in the process.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / pharmacology*
  • Animals
  • Benzimidazoles / pharmacology
  • Diazoxide / pharmacology*
  • Dibutyryl Cyclic GMP / pharmacology*
  • Dinoprostone
  • Drug Synergism
  • Endorphins / physiology
  • Hyperalgesia / chemically induced
  • Hyperalgesia / psychology
  • Kinetics
  • Male
  • Membrane Proteins / agonists
  • Membrane Proteins / drug effects*
  • Naloxone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Nitric Oxide / physiology
  • Nitroprusside / pharmacology*
  • Pain Measurement / drug effects
  • Potassium Channel Blockers / pharmacology
  • Potassium Channels
  • Rats
  • Rats, Wistar

Substances

  • Analgesics
  • Benzimidazoles
  • Endorphins
  • Membrane Proteins
  • Narcotic Antagonists
  • Potassium Channel Blockers
  • Potassium Channels
  • mitochondrial K(ATP) channel
  • NS 1619
  • Nitroprusside
  • Nitric Oxide
  • Dibutyryl Cyclic GMP
  • Naloxone
  • Dinoprostone
  • Diazoxide